Home | MyCME | All CME | Blog | Psychlopedia

CME Activities About depression

Choose another keyword:

From the series JCP CME Activities

From the series Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment

Supported by an educational grant from Teva Pharmaceuticals.

From the series Early Recognition and Treatment of Tardive Dyskinesia in Patients with Mood Disorders and Schizophrenia

Supported by an educational grant from Neurocrine Biosciences, Inc.

From the series PCC CME Activities

From the series A Multidisciplinary Approach for Addressing Challenges in Alzheimer’s Disease

Supported by educational grants from ACADIA Pharmaceuticals Inc.; Allergan; Avanir Pharmaceuticals, Inc.; and Biogen MA, Inc.

From the series Hands-On TMS Symposium 2019

Supported by TMS Health Solutions.

In-kind support provided by Brainsway, Magstim, MagVenture, and Neuronetics.


From the series Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia

Supported by an educational grant from Indivior Inc.

From the series New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

From the series Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia

Supported by an educational grant from Alkermes, Inc.

From the series Overcoming Challenges in Diagnosis and Depression Management in Pediatric Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

From the series Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments

Supported by an educational grant from Lilly.

From the series Current and Emerging Treatments to Address Unmet Needs in MDD

Supported by an educational grant from Alkermes, Inc.

From the series Getting to Remission: Differentiating Residual Symptoms From Treatment Side Effects in Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

From the series Effective Management Approaches for Psychosis in Patients With Parkinson Disease

Supported by an educational grant from Acadia Pharmaceuticals Inc.

From the series Improving the Diagnosis and Treatment of Adolescent Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

From the series Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis

Supported by an educational grant from Neurocrine Biosciences, Inc.

From the series Parkinson Disease: Current Trends in Treatment and Unmet Needs

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Reconsidering Insomnia as a Disorder Rather Than Just a Symptom in Psychiatric Practice

Supported by an educational grant from Merck & Co., Inc.

From the series Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

From the series Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?

Supported by an educational grant from Alkermes, Inc.

From the series What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options

Supported by an educational grant from Neurocrine Biosciences, Inc.

From the series Remove

From the series Improving Remission Rates in Major Depressive Disorder: A Case-Based Approach

Supported by an educational grant from Otsuka America Pharmaceutical Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., Medical Education Resources, and CMEology.

From the series Emerging Treatment Strategies for Patients With Tardive Dyskinesia

Supported by an educational grant from Teva Pharmaceuticals.

From the series Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?

Supported by an educational grant from Otsuka America Pharmaceutical Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., Medical Education Resources, and CMEology.

From the series Diagnosing and Treating Patients With Mixed Features

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

From the series Advanced Topics in Major Depressive Disorder: Practical Strategies to Improve Remission

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., and CMEology.

From the series Challenges in the Recognition and Treatment of Binge-Eating Disorder

This Supplement is derived from the planning teleconference series “Challenges in the Recognition and Treatment of Binge-Eating Disorder,” which was held in May, June, and July 2016, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Shire.

From the series Recognition and Treatment of Pediatric Bipolar Disorder

This Supplement is derived from the planning teleconference series “Recognition and Treatment of Pediatric Bipolar Disorder,” which was held in August and September 2015, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Forest Laboratories, Inc.

From the series Improving the Care and Management of Patients With Inadequate Response to Depression Treatment

Supported by an educational grant from Otsuka Pharmaceutical Development and Commercialization, Inc.

From the series Enhancing Approaches to the Identification and Management of Pseudobulbar Affect

Supported by an educational grant from Otsuka America Pharmaceutical, Inc. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., and CMEology.

From the series Achieving Remission and Recovery in Depression With Anxiety

Supported by an educational grant from Forest Laboratories, Inc.

From the series Measuring and Managing Cognitive Impairment in Schizophrenia

This Supplement is derived from the planning teleconference series “Measuring and Managing Cognitive Impairment in Schizophrenia,” which was held in April and May 2015 and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from FORUM Pharmaceuticals.

From the series Sleep Disorders in the Psychiatric Setting

Supported by an educational grant from Merck.

From the series Strategies to Improve Outcomes for Primary Care Patients With Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.

From the series Recognizing and Treating Excessive Daytime Sleepiness and Narcolepsy

Supported by an educational grant from Jazz Pharmaceuticals.

From the series Complicated Major Depressive Disorder

Suppported by educational grants from Eli Lilly and Company and Bristol-Myer Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series What Psychiatric Nurses Need to Know About Bipolar Disorder

Supported by an educational grant from AstraZeneca.

From the series Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

From the series Criminal Forensic Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Cognition in the Depressed Patient

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.

From the series Understanding and Coping With Binge Eating Disorder: The Patient’s Perspective

Supported by an educational grant from Shire.

From the series Overcoming Challenges in the Diagnosis and Management of ADHD in African American Adults

Supported by an educational grant from Shire.

From the series Cause and Effect in Bipolar Depression: Misdiagnosis Leads to Inappropriate Treatment, Clinical Complications, and Adverse Outcomes

Supported by educational grants from Sunovion Pharmaceuticals and Supernus Pharmaceuticals.

From the series New Strategies in Sleep

Supported by an educational grant from Merck & Co.

From the series Challenges in the Recognition and Management of ADHD in Hispanic Adults in the United States

Supported by an educational grant from Shire.

From the series Making Connections Between Science and Symptoms in Schizophrenia

Supported by an educational grant from Genentech.

From the series Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Treating and Caring for the Patient With Moderate-to-Severe Alzheimer's Disease

Supported by an educational grant from Forest Laboratories, Inc.

From the series The Impact of Oral Medications on the Treatment of Multiple Sclerosis

Supported by an educational grant from Genzyme, a Sanofi Company, and Novartis Pharmaceuticals Corporation.

From the series Improving Depression Outcomes by Providing Safe and Effective Care in the Rural Setting

Supported by an educational grant from Forest Research Institute, a subsidiary of Forest Laboratories, Inc.

From the series Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Supported by an educational grant from Lilly USA, LLC.

From the series Controversies in the Psychopharmacology of Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

From the series Appropriate Management of Multiple Sclerosis in Primary Care

Supported by educational grants from EMD Serono and Genzyme, a Sanofi Company.

From the series Update on Best Practices for Managing Bipolar Depression

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

From the series Measurement-Based Strategies to Assess and Manage Schizophrenia   

Supported by an educational grant from Genentech.

From the series Benefits and Barriers to Using Long-Acting Injectable Antipsychotics in Schizophrenia

Supported by an educational grant from from Otsuka America Pharmaceutical, Inc. and Lundbeck.

From the series Improving the Diagnosis and Management of Depression in Bipolar Disorder

Supported by an educational grant from Teva Pharmaceuticals.

From the series Improving the Differential Diagnosis and Treatment of Bipolar Depression in Primary Care

Supported by an educational grant from Sunovion Pharmaceuticals.

From the series Update on Treatment-Resistant Depression: Translating Clinical Science Into Effective Therapies

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

From the series Restless Legs Syndrome: Recognition, Diagnosis, and Treatment of a Common Sleep Disorder

Supported by an educational grant from UCB, Inc.

From the series Treatment of Depression in Primary Care: Using Tools to Improve Outcomes

Supported by an educational grant from Forest Laboratories, Inc.

From the series Depression: Managing the Full Range of Symptoms to Achieve Lasting Remission

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Lundbeck.

From the series Working Together to Restore Mental Well-Being and Address Domestic Violence Among Veterans: A Call To Action

Supported by an educational grant from Blue Shield of California Foundation.

From the series Complicated OCD: Issues of Comorbidity and Clinical Challenges

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the Lindner Center of HOPE

From the series Understanding the Sleep-Wake Cycle: Sleep, Insomnia, and the Orexin System

Supported by an educational grant from Merck & Co., Inc.

From the series Assessing and Managing Pain and Major Depression With Medical Comorbidities

Supported by an educational grant from Lilly.

From the series Schizophrenia: Using Long-Acting Injectable Antipsychotics to Improve Treatment Adherence

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

From the series The Effects of the Affordable Care Act on the Practice of Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series ADHD in College, Phase II: Managing the Risk of Misuse, Abuse, and Diversion

Supported by an independent medical education grant from Shire.

From the series Caring for Returning Veterans: Meeting Mental Health Needs

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Alzheimer's Disease: The Importance of Early Diagnosis and Appropriate Management

Supported by an educational grant from Lilly USA, LLC.

From the series Military- and Sports-Related Mild Traumatic Brain Injury: Clinical Presentation, Management, and Long-Term Consequences

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Expired Other

From the series Negative Symptoms in Schizophrenia: Treatment Gaps and Unmet Needs

Supported by an educational grant from Genentech

From the series The Effect of Marijuana Use on the Risk for Schizophrenia

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Depression, Pain, and Comorbid Medical Conditions

Supported by an educational grant from Lilly USA, LLC.

From the series Improving Outcomes in Multiple Sclerosis Through Early Diagnosis and Effective Management

Supported by an educational grant from Pfizer.

From the series A Fresh Look at Monoamine Oxidase Inhibitors for Depression

Supported by an educational grant from Mylan Specialty L.P. (formerly known as Dey Pharma, L.P.)

From the series NCDEU Poster Session 2012

From the series New Treatment Approaches for Major Depressive Disorder  

Supported by an educational grant from Forest Laboratories.

From the series Schizophrenia: When First-Line Treatment Fails

Supported by an educational grant from Teva.

From the series Diagnosing and Managing Patients With Dementia

Supported by an educational grant from Pfizer.

From the series ADHD in College: Seeking and Receiving Care During the Transition From Child to Adult

Supported by an independent medical educational grant from Shire

From the series Overview of Current Issues in the Management of Multiple Sclerosis

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series International Consensus Group on Depression Prevention in Bipolar Disorder

Supported by an educational grant from GlaxoSmithKline.

From the series Alzheimer's Disease: Implications of the Updated Diagnostic and Research Criteria

Independently developed by The CME Institute of Physicians Postgraduate Press, Inc.

From the series Fibromyalgia: Creating a Patient-Centered Diagnostic and Therapeutic Roadmap

Supported by an educational grant from Pfizer.

From the series 2011 ICBD Conference Coverage: Practical Applications of New Research in Bipolar Disorder

Supported by an educational grant from Bristol-Myers Squibb.

From the series Evidence for Using L-Methylfolate Combined With Antidepressants in MDD

Supported by an educational grant from Pamlab, LLC.

From the series Depression: When Initial Therapy Fails

Supported by an educational grant from AstraZeneca.

From the series Using Diagnostic and Assessment Tools for Adolescents With ADHD

Supported by an educational grant from Shire.

From the series Using Moderator-Based Algorithms  and Electronic Medical Records  to Achieve Optimal Outcomes in Depression

Jointly sponsored by Vanderbilt School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc. Vanderbilt School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc., express appreciation to the following company for i

From the series The Current Crisis of Confidence in Antidepressants

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series New Approaches to Managing Schizoaffective Disorder From Diagnosis to Treatment

Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

From the series Looking Past First-Line Therapy for Major Depressive Disorder

Supported by an educational grant from AstraZeneca

From the series Considerations in Managing Schizophrenia in Adolescents

Supported by an educational grant from Eli Lilly and Company.

From the series Challenges in the Long-Term Treatment of Schizophrenia

Supported by an educational grant from Eli Lilly and Company.

From the series Improving Outcomes in Bipolar Disorder: From Early Recognition and Treatment to Remission

Supported by an educational grant from Eli Lilly and Company.

From the series Strategies for Selecting Treatment and Mitigating Risk in Patients With Chronic Pain

Supported by an unrestricted educational grant from Purdue Pharma LP.

From the series Strategies for the Long-Term Treatment of Bipolar Disorder in Children and Adults

Supported by an educational grant from Pfizer.

From the series Improving the Recognition and Treatment of Bipolar Disorder in Primary Care

Supported by an educational grant from AstraZeneca

From the series Improving Executive Function in Adults With ADHD

Supported by an educational grant from Eli Lilly and Company.

From the series Improving Outcomes in Depression

Supported by an educational grant from Eli Lilly and Company.

From the series International Consensus Group on Depression

Supported by an educational grant from GlaxoSmithKline.

From the series Tackling Partial Remission to Depression Treatment

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series The Use of Complementary and Alternative Medicines to Achieve Remission in Major Depressive Disorder

Supported by an educational grant from Pamlab, LLC.

From the series What Is Bipolar Disorder?

These activities are part of the Bipolar Disorder Unit, which was supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series An Introduction to the Clinical Correlates of Disrupted Slow-Wave Sleep

Supported by an educational grant from sanofi-aventis.

From the series Following Up on The Expert Consensus Guidelines for Geriatric Depression

Supported by an educational grant from Eli Lilly and Company.

From the series Depression in Latinos: A Focus on Overcoming Barriers

Supported by an educational grant from Wyeth.

From the series Bipolar Disorder in Children and Adolescents

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Definition and Management of Suicidality in Psychiatric Patients

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Balancing the Equation: Managing Medical Comorbidities in Patients With Severe Mental Illness

Supported by an educational grant from Pfizer Inc.

From the series Expired Case & Comment

From the series Maintenance of Certification in Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

From the series Bipolar Depression

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series What Is Depression?

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

From the series MDD in Women: Focus on Reproductive Events

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology

From the series Using Atypical Antipsychotics to Optimize the Clinical Management of Patients With Mental Illnesses

Supported by an educational grant to i3 CME from Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc.

From the series Depression in the Elderly

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

From the series Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection

Supported by an educational grant from Eli Lilly and Company.

From the series ADHD and Comorbid Disorders in Adults

Supported by an educational grant from Eli Lilly and Company.

From the series Major Depressive Disorder

These activities are part of the Depression Unit, which is supported by educational grants from Eli Lilly and Company and Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Easing the Burden of Treatment-Resistant Depression

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Depression and Pain

Supported by an educational grant from Eli Lilly and Company.

From the series Depression, Pain, and Physical Symptoms

These activities are part of the Depression Unit, which is supported by educational grants from Eli Lilly and Company and Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Easing the Burden of Bipolar Disorder: From Urgent Situations to Remission

Supported by an educational from Eli Lilly and Company.

From the series Understanding Fibromyalgia and Its Related Disorders

Supported by an educational grant from Eli Lilly and Company.

From the series Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap

All content was developed by the Expert Knowledge Systems division of Comprehensive Neuroscience, Inc., and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational from Bristol-Myers Squibb.

From the series Clinical Insights Into Pharmacogenetics and Schizophrenia

Supported by an educational grant from Vanda Pharmaceuticals, Inc.

From the series Pain and the Brain

Supported by an educational grant from Eli Lilly and Company.

From the series The Use of Atypical Antipsychotics in Pediatric Psychiatric Disorders

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Influencers of Treatment Success in Schizophrenia and Bipolar Disorder

This Supplement was independentaly developed by CME Outfitters and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Bristol-Myers Squibb and Otsuka Pharmaceutical.

From the series Maximizing Efficacy of Antidepressants Beyond Selective Serotonin Reuptake Inhibitors

Supported by an educational grant from GlaxoSmithKline Services Unlimited.

From the series Conference Coverage: 20th European College of Neuropsychopharmacology (ECNP) Congress

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

From the series Raising the Bar in Schizophrenia by Treating to Remission

Supported by an educational grant from Janssen LP administered by Ortho-McNeil Janssen Scientific Affairs, L.L.C.

From the series Diagnosis and Treatment Strategies for Mixed Episodes in Bipolar Disorder

Supported by an educational grant from Eli Lilly and Company.

From the series Presentations From the Seventh International Conference on Bipolar Disorder

Supported by educational grants from Eli Lilly and Company, Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc, and Pfizer Inc.

From the series Narcolepsy and Excessive Daytime Sleepiness: From the Bench to the Bedside

This activity was independently developed by The Chatham Institute pursuant to an educational grant from Jazz Pharmaceuticals, Inc. The CME Institute of Physicians Postgraduate Press, Inc., an ACCME accredited provider, was the joint sponsor.

From the series Atypical Depression: Management Challenges and New Treatment Advances

Supported by an educational grant from Bristol-Myers Squibb Company.

From the series Cognitive Impairment Associated With Depression in the Elderly

Supported by an educational grant from Forest Pharmaceuticals, Inc.

From the series Managing Bipolar Disorder From Urgent Situations to Maintenance Therapy

Supported by an educational grant from Eli Lilly and Company.

From the series Weighing the Evidence: Weight Management Insights for Treating Major Mental Illness

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine, ACCELMED, and the CME Institute of Physicians Postgraduate Press, Inc. This activity was supported by an educational grant from Eli Lilly and Company.

From the series ADHD and Comorbid Substance Use Disorder

Supported by an educational grant from Shire Pharmaceuticals Inc.

From the series Mixed Depression in Bipolar Disorders: Diagnosis and Treatment Strategies

Supported by an educational grant from Eli Lilly and Company.

From the series The Role of Folate in Depression and Dementia

Supported by an educational grant from PamLab, L.L.C.

From the series Strategies to Integrate Physical Health Care Into Mental Health

These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Letters & Sciences pursuant to an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Special Issues Related to the Management of Bipolar Disorder in Women: Tolerability of Treatment

Supported by an educational grant from GlaxoSmithKline.

From the series Translating Evidence on Depression and Physical Symptoms into Effective Clinical Practice

Supported by an educational grant from Eli Lilly and Company.

From the series Distance Rounds

These activities were independently developed by Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

From the series Monoamine Oxidase Inhibitors Revisited: Their Role in Depressive Disorders

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Outfitters and the CME Institute of Physicians Postgraduate Press, Inc. This activity was supported by an educational grant from Bristol-Myers Squibb Company.

From the series The Art and Science of Switching Antipsychotic Medications

These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and SciMed pursuant to an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

From the series Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

These activities were independently developed by the University of California, Irvine School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Wyeth Pharmaceuticals.

From the series Understanding Neuronal Pathways: Novel Targets for the Management of Insomnia

This activity was supported by an educational grant from Merck and Lundbeck. Editorial assistance and honoraria were provided by Physicians Postgraduate Press, Inc., and SciMed.

From the series Managing ADHD in Children, Adolescents, and Adults With Comorbid Anxiety

Supported by an educational grant from Eli Lilly and Company.

From the series Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression

Supported by an educational grant from Neuronetics, Inc.

From the series Evaluating the Evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and Beyond

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Health and Wellness Education Partners pursuant to an educational grant from Pfizer Inc and additional financial support from HWP Publishing.

From the series Practical Applications of Recent Antipsychotic Effectiveness Data

Supported by an educational grant from Eli Lilly and Company.

From the series ADHD: Applying Practice Guidelines to Improve Patient Outcome and Executive Function

Supported by an educational grant from McNeil Pharmaceuticals.

From the series Practical Pharmacotherapeutic Management Strategies for Patients With Alcohol Dependence

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Fusion Medical Education pursuant to an educational grant from Alkermes, Inc. and Cephalon, Inc.

From the series New Developments in Addiction Treatment

Supported by an educational grant from Cephalon, Inc.

From the series Psychiatry in Brief: Insomnia and Emerging Therapies: Treating the Whole Patient

Supported by an educational grant from sanofi-aventis U.S.

From the series Improving Cognitive Function and Functional Outcome in Severe Mental Illness

Supported by an educational grant from Bristol-Myers Squibb Company.

From the series Social Anxiety Disorder: Diagnosis, Outcome, Mechanisms, and Management

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Imprint Science pursuant to an educational grant from Forest Laboratories, Inc.

From the series Recent Advances in the Treatment of Depression in the Presence of Physical Symptoms

Supported by an educational grant from Eli Lilly and Company.

From the series Managing Patients With Vascular Disease and Depression

Supported by an educational grant from Forest Laboratories, Inc.

From the series Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD): A Clinical View

Supported by an educational grant from GlaxoSmithKline.

From the series New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder

Supported by an educational grant from Cephalon, Inc.

From the series The Challenges of Dual Diagnosis: Managing Substance Abuse in Severe Mental Illness

Supported by an educational grant from AstraZeneca Pharamaceuticals LP.

From the series Emerging Therapies for Bipolar Depression

Supported by an educational grant from Cyberonics, Inc.

From the series The Role of Dopamine and Norepinephrine in Depression and Antidepressant Treatment

Supported by an educational grant from GlaxoSmithKline.

From the series Managing Nonadherence in Schizophrenia: The Role of Long-Acting Agents

Supported by an educational grant from Janssen Medical Affairs, L.L.C.

From the series Distance Rounds

These activities were independently developed by Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

From the series Identifying and Managing Depression in the Medical Patient

Supported by an educational grant from Eli Lilly and Company.

From the series Review of the Pharmacologic Management of Depression

Supported by an educational grant from GalxoSmithKline.

From the series Bipolar Reports

Supported by an educational grant from GlaxoSmithKline.

From the series After the Tsunami: Mental Health Challenges to the Community for Today and Tomorrow

This activity was independtly developed by the CME Institute of Physicians Postgraduate Press, Inc., and PPS International Communications pursuant to an educational grant from Pfizer Inc.

From the series Sleep: New Frontiers in Psychiatry and Primary Care

Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

From the series The Recognition and Management of Bipolar Disorder With Comorbid Anxiety

Supported by an educational grant from Janssen Medical Affairs, L.L.C.

From the series Focus on Bipolar Disorder Treatment

Supported by an educational grant from GlaxoSmithKline.

From the series Management of Autism and Its Related Disorders

Supported by an educational grant from Janssen Medical Affairs, L.L.C.

From the series Managing Bipolar Depression